Evidence map›Paper›PMID 41400317›Full record

ArticleInvestigative ophthalmology & visual science2025

Evidence Supporting Autotaxin as a Potential New Drug Treatment Target in Patients With Advanced Diabetic Retinopathy.

Harumasa Yokota, Hiroki Hayashi, Hironori Nakagami, Akifumi Kushiyama, Junya Hanaguri, Megumi Honjo, Makoto Aihara, Makoto Kurano, Koji Igarashi, Sakura Kushiyam and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Harumasa YokotaDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.
Hiroki HayashiDepartment of Health Development and Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Hironori NakagamiDepartment of Health Development and Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.
Akifumi KushiyamaDepartment of Pharmacotherapy, Meiji Pharmaceutical University, Tokyo, Japan.
Junya HanaguriDivision of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan.
Megumi HonjoDepartment of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Makoto AiharaDepartment of Ophthalmology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Makoto KuranoDepartment of Clinical Laboratory, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Koji IgarashiBioscience Division, Reagent Development Department, AIA Research Group, TOSOH Corporation, Ayase, Japan.
Sakura KushiyamTokyo Gakugei University, Tokyo, Japan.
Satoru YamagamiDivision of Ophthalmology, Department of Visual Sciences, Nihon University School of Medicine, Tokyo, Japan.
Taiji NagaokaDepartment of Ophthalmology, Asahikawa Medical University, Asahikawa, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The purpose of this study was to test the hypothesis that increased intraocular autotaxin (ATX) levels contribute to the progression of diabetic retinopathy (DR), we investigated ATX levels in the vitreous of patients with type 2 diabetes with proliferative diabetic retinopathy (PDR) and assessed the effect of an ATX peptide vaccine (VA) in a db/db mouse model of type 2 diabetes. Methods: Vitreous samples were collected from participants with PDR and from controls with non-diabetic ocular diseases. ATX, lipid mediator, and cytokine levels were measured by ELISA. VA or a control vaccine was administered to db/db mice at 7 and 9 weeks of age. Antibody titers were quantified at 15 weeks of age. Retinal function and blood flow responses to systemic hyperoxia and flicker stimulation were assessed every 2 weeks from age 10 to 14 weeks using electroretinography (ERG) and laser speckle flowgraphy. Results: Vitreous ATX levels were significantly higher in PDR than in epiretinal membrane or lens dislocation, and positively correlated with ICAM-1, TGF-β1, and adiponectin. VA improved blood glucose levels but not resting blood flow. However, VA restored blood flow responses to both hyperoxia and flicker stimulation and improved ERG implicit times compared with the control vaccine. Conclusions: Elevated ATX may contribute to the progression of advanced DR. Vaccination against ATX preserved neurovascular function in early diabetic retinopathy in mice. Further studies are needed to clarify its role in DR progression.

Indexed as

Diabetic RetinopathyPhosphoric Diester HydrolasesVitreous BodyAdultAgedAnimalsDiabetes Mellitus, Type 2Disease Models, AnimalDisease ProgressionElectroretinographyEnzyme-Linked Immunosorbent AssayFemaleHumansLaser-Doppler FlowmetryLysophospholipase DMaleLysophospholipase DPhosphoric Diester Hydrolases

Identifiers

PMID41400317
PMCPMC12720184

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.